Avalo Therapeutics Q3 net loss narrows to $18.9 million; cash totals $462.8 million
Avalo Therapeutics reported a third-quarter 2026 net loss of $18.9 million, or $0.34 per share, down from $30.6 million, or $2.19 per share, a year earlier. The filing attributes the narrower loss mainly to a change in the fair value of a derivative liability, while operating expenses rose $4.2 million, and the company says its cash is expected to fund operations into 2029.
Key points
- Net loss was $18.9 million for the quarter ended September 30, 2026, a decrease of $11.7 million from the prior-year quarter.
- Total operating expenses rose $4.2 million to $23.4 million, led by research and development ($15.0 million) and general and administrative ($8.4 million) costs.
- Cash, cash equivalents and investments were $462.8 million as of September 30, 2026, expected to fund operations into 2029.
- Avalo expects FDA feedback on its abdakibart development plan by year-end 2026 and plans to start a Phase 3 program in the first half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.